WAM
ABCL icon

Worth Asset Management’s AbCellera Biologics ABCL Stock Holding History

Worth Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,750
Closed -$40K – 452
2022
Q2 		$40K Hold
3,750
– – 0.03% 218
2022
Q1 		$25K Buy
+3,750
New +$35.5K 0.02% 280

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Worth Asset Management's ABCL Position: Q3 2022 in Review

Worth Asset Management sold out of AbCellera Biologics (ABCL) in Q3 2022, closing a stake of 3,750 shares — an estimated $40K sold.

Worth Asset Management first reported a position in ABCL in Q1 2022 and held it in 2 quarters. The position peaked at $40K in Q2 2022. 190 funds tracked by Wall St. Rank hold ABCL as of Q3 2022.

  • Worth Asset Management reported no remaining AbCellera Biologics position as of Q3 2022 after selling out during the quarter.
  • Worth Asset Management sold 3,750 AbCellera Biologics shares in Q3 2022, an estimated $40K.
  • Worth Asset Management first reported a position in AbCellera Biologics in Q1 2022 and held it in 2 quarters.
  • Worth Asset Management's AbCellera Biologics position peaked at $40K in Q2 2022.
  • 190 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2022.

Based on Worth Asset Management's 13F filing for Q3 2022, filed 7 Oct 2022.